Cargando…

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials

Treatment intensification to maximize disease control and reduced intensity approaches to minimize the risk of late sequelae have been evaluated in newly diagnosed Hodgkin lymphoma. The influence of these interventions on the risk of secondary malignant neoplasms, progression-free survival and overa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichenauer, Dennis A., Becker, Ingrid, Monsef, Ina, Chadwick, Nicholas, de Sanctis, Vitaliana, Federico, Massimo, Fortpied, Catherine, Gianni, Alessandro M., Henry-Amar, Michel, Hoskin, Peter, Johnson, Peter, Luminari, Stefano, Bellei, Monica, Pulsoni, Alessandro, Sydes, Matthew R., Valagussa, Pinuccia, Viviani, Simonetta, Engert, Andreas, Franklin, Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622859/ https://www.ncbi.nlm.nih.gov/pubmed/28912173 http://dx.doi.org/10.3324/haematol.2017.167478

Ejemplares similares

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
por: André, Marc P. E., et al.
Publicado: (2020)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Therapy-Related Myeloid Neoplasms in Patients Treated for Hodgkin Lymphoma
por: Eichenauer, D.A., et al.
Publicado: (2011)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2022)

Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond
por: Perrone, Salvatore, et al.
Publicado: (2023)

Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
por: Momotow, Jesko, et al.
Publicado: (2021)

Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
por: Retsky, Michael, et al.
Publicado: (2004)

Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour
por: Demicheli, Romano, et al.
Publicado: (2004)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

Survival in Hodgkin's Disease
por: Meighan, S. S., et al.
Publicado: (1963)

Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
por: Behringer, K, et al.
Publicado: (2013)

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
por: Viviani, S., et al.
Publicado: (1998)

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
por: Swain, Sandra M., et al.
Publicado: (2022)

Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
por: De Sanctis, Vitaliana, et al.
Publicado: (2012)

Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma
por: Rodday, Angie Mae, et al.
Publicado: (2021)

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021)

Improved survival time trends in Hodgkin's lymphoma
por: Koshy, Matthew, et al.
Publicado: (2016)

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
por: Engert, Andreas, et al.
Publicado: (2017)

The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi
por: Minoia, Carla, et al.
Publicado: (2021)

Introducing the HemaSphere Controversies Series
por: Eichenauer, Dennis A., et al.
Publicado: (2019)

The influence of marital status on the survival of patients with Hodgkin lymphoma
por: Wang, Fangfang, et al.
Publicado: (2017)

Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi
por: Nassi, Luca, et al.
Publicado: (2022)

Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
por: Eichenauer, Dennis A., et al.
Publicado: (2023)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
por: Bröckelmann, Paul, et al.
Publicado: (2023)

Atopy--a favourable prognostic factor for survival in Hodgkin's disease.
por: Amlot, P. L., et al.
Publicado: (1983)

T‐Cell Phenotype Is Associated with Decreased Survival in Non‐Hodgkin's Lymphoma
por: Shimizu, Kazuyuki, et al.
Publicado: (1989)

Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma
por: Nuersulitan, Reyizha, et al.
Publicado: (2021)

HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana
por: Moahi, Kaelo, et al.
Publicado: (2022)

Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival
por: Tarella, Corrado, et al.
Publicado: (2014)

Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
por: Oliva, Stefano, et al.
Publicado: (2021)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
por: Di Molfetta, Sergio, et al.
Publicado: (2022)

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma
por: Borchmann, Sven, et al.
Publicado: (2018)

Survival from non-Hodgkin lymphoma in England and Wales up to 2001
por: Johnson, P W M
Publicado: (2008)

Survival from non-Hodgkin lymphoma in England and Wales up to 2001
por: Rachet, B, et al.
Publicado: (2008)

The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments
por: Bari, Alessia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7ca1u243g6erhum20af7g65anj